Vita Therapeutics, Inc.

Based in the US, Vita Therapeutics, Inc. is a biotechnology company specializing in advanced cellular medicine, focusing on the development of engineered cellular therapies using Induced Pluripotent Stem Cells (iPSCs) to treat genetic disorders. Vita Therapeutics, Inc. was founded in 2018 in Baltimore, US, and specializes in cellular medicine through innovative applications of iPSCs.

The company has completed 2 deals, with its most recent funding round being a Series B of USD 30. 89 mn raised on October 11, 2022, involving investors such as Cambrian Biopharma and Cedars-Sinai Health System. The company was co-founded by Douglas Falk and Peter Andersen, with Douglas Falk serving as the CEO. Vita Therapeutics specializes in advanced cellular medicine through the innovative use of Induced Pluripotent Stem Cells (iPSCs), derived from somatic cells using the Yamanaka Factors.

These stem cells can differentiate into any human cell type, enabling the production of tailored cell types intended to replace defective cells in patients. Key offerings include the Autologous Approach for patient-specific therapies and the Allogeneic Approach for universal therapy solutions, focusing on significant medical needs in genetic disorders such as LGMD2A and FSHD. The company serves clinical institutions and research organizations primarily in North America and Europe, targeting markets with high demand for regenerative medicine solutions. Vita Therapeutics generates revenue through collaborations and partnerships with healthcare providers and research institutions, focusing on the commercialization of its cell therapy technologies.

The revenue model involves licensing agreements and service contracts, with clients engaging Vita for the development and supply of engineered cellular therapies. Revenue sources include milestone payments and potential royalties based on developed therapeutic applications, with pricing plans tailored to the complexities of the therapies offered, particularly for flagship products associated with the company’s proprietary iPSC technologies. In October 2022, Vita Therapeutics raised USD 30. 89 mn in Series B funding to support its new product pipeline.

The company plans to leverage this funding to drive the development of upcoming products aimed at addressing unmet medical needs and expanding its portfolio of engineered cellular therapies. Additionally, Vita is looking to expand into new markets across North America and Europe by 2024, targeting clinical institutions and research organizations that require advanced regenerative solutions. The funding will facilitate these initiatives, enhancing the company's capacity to innovate in cellular medicine.